HiTel launch - PowerPoint PPT Presentation

1 / 57
About This Presentation
Title:

HiTel launch

Description:

HiTel launch – PowerPoint PPT presentation

Number of Views:20
Avg rating:3.0/5.0
Slides: 58
Provided by: rodhu
Category:
Tags: hitel | launch | tug

less

Transcript and Presenter's Notes

Title: HiTel launch


1
(No Transcript)
2
MGMS 25th Anniversary Meeting
Working with proteins Roderick E Hubbard
  • 13th March 2007

3
Working with Proteins a personal per (and
retro) spective
  • The Past
  • What was a driver for MGMS?
  • Life before and after 1983
  • The Past and Present
  • Hardware developments, 1987 2007
  • Methods developments, 1987 2007
  • Determining structure
  • Predicting structure, conformation, mechanism and
    interactions
  • Structure-based drug discovery
  • The Future
  • Priorities for the next decade

4
Working with Proteins a personal per (and
retro) spective
  • The Past
  • What was a driver for MGMS?
  • Life before and after 1983
  • The Past and Present
  • Hardware developments, 1987 2007
  • Methods developments, 1987 2007
  • Determining structure
  • Predicting structure, conformation, mechanism and
    interactions
  • Structure-based drug discovery
  • The Future
  • Priorities for the next decade

5
(No Transcript)
6
(No Transcript)
7
1980
8
1980
9
1982
10
1982
11
1982
12
1982
13
1983
PERQ computer Metheus colour
Evans and Sutherland PS300
raster
graphics (shared)
14
1985
Evans and Sutherland PS300 (130k)
15
1982 - 1986
Evans and Sutherland PS300 Vector
graphics Continual refresh from data network Host
/ graphics connection Programming a challenge
16
1982 - 1986
1982 1986 Evans and Sutherland PS300 Vector
graphics Continual refresh from data network Host
/ graphics connection Programming a
challenge Dot surfaces
17
1982 - 1986
1982 1986 Evans and Sutherland PS300 Vector
graphics Continual refresh from data network Host
/ graphics connection Programming a
challenge Dot surfaces Mesh surfaces
18
1986
Silicon Graphics Raster graphics
workstation 65k First SG imported into Europe
!!
19
1986
Raster graphics workstation Fast computing behind
space filling graphics More memory Cheaper
disks Menu systems Interactive modelling
20
Working with Proteins a personal per (and
retro) spective
  • The Past
  • What was a driver for MGMS?
  • Life before and after 1983
  • The Past and Present
  • Hardware developments, 1987 2007
  • Methods developments, 1987 2007
  • Determining structure
  • Predicting structure, conformation, mechanism and
    interactions
  • Structure-based drug discovery
  • The Future
  • Priorities for the next decade

21
1988
22
1990
23
1991
24
1993
By the mid-1990s, molecular graphics equipment
available to all reasonably funded laboratories.
Workstation for around 5k
25
An excursion into virtual reality
1992-4
26
(No Transcript)
27
Working with Proteins a personal per (and
retro) spective
  • The Past
  • What was a driver for MGMS?
  • Life before and after 1983
  • The Past and Present
  • Hardware developments, 1987 2007
  • Methods developments, 1987 2007
  • Determining and analysing structure
  • Predicting structure, conformation, mechanism and
    interactions
  • Structure-based drug discovery
  • The Future
  • Priorities for the next decade

28
Determining protein structures
  • Advances in protein production, crystallisation,
    x-ray sources, data processing, structure
    solution and refinement
  • Complemented by advances in streamlined packages
    for solving and refining structures gt high
    throughput crystallography

29
ER Ligands
Raloxifene (RAL) Antagonist in breast and uterine
tissue but agonist in bone and heart Licensed for
treatment of osteroporosis
17b-Oestradiol (E2) most potent, endogenous
oestrogen (Kd 0.1nM) promotes cell proliferation
in female reproductive tissues plays an important
role in maintenance of cardiovascular system,
bone and brain in both sexes
30
Cell Biology of Estrogen Action
CELL MEMBRANE
CYTOPLASM
NUCLEUS
Receptor held in inactive Heat Shock Protein
complex
DNA
Gene
31
Molecular Biology of Estrogen Action
Estrogen receptor (ER) binds to response element
(ERE) and recruits co-activators / co-repressors
that instruct a series of large multi-protein
complexes to
A
ER
ER
Polymerase
TAFs
complex
TBP
DNA
ERE TATA
B
ER
ER
Polymerase
TAFs
complex
TBP
DNA
ERE TATA
32
Structural Biology of the Estrogen Receptor (ER)
Receptor has a distinctive domain structure with
a DNA binding domain (DBD) and Ligand Binding
Domain (LBD)
AF-1 (a) DNA binding
ligand / AF-2
33
Protein Crystallography
Crystal
Diffraction
34
Examples of analysis ER story
35
Working with Proteins a personal per (and
retro) spective
  • The Past
  • What was a driver for MGMS?
  • Life before and after 1983
  • The Past and Present
  • Hardware developments, 1987 2007
  • Methods developments, 1987 2007
  • Determining and analysing structure
  • Predicting structure, conformation, mechanism and
    interactions
  • Structure-based drug discovery
  • The Future
  • Priorities for the next decade

36
(No Transcript)
37
(No Transcript)
38
Protein Science, (1998) 7, 1359 1367
39
Working with Proteins a personal per (and
retro) spective
  • The Past
  • What was a driver for MGMS?
  • Life before and after 1983
  • The Past and Present
  • Hardware developments, 1987 2007
  • Methods developments, 1987 2007
  • Determining and analysing structure
  • Predicting structure, conformation, mechanism and
    interactions
  • Structure-based drug discovery
  • The Future
  • Priorities for the next decade

40
Virtual Screening - rDock
41
Virtual Screening - rDock
  • Contributions to success
  • Quality of docking library (diversity,
    properties)
  • Target model conformation / solvent
  • Docking performance
  • Post-screening selection of compounds for assay

42
Hit Generation Hsp90
  • rDock
  • 807 compounds purchased
  • Found 10 hits (lt20mM)
  • Included known hit four other members of same
    series
  • ? indicative SAR (5-150 mM)
  • 2 other classes of compounds

rDock class 2 rDock class 3 (0.9mM) gt
backup (6mM) oral candidate
lead (5mM) gt clinical candidate
43
Lead Optimisation
  • High Throughput X-ray gt rapid structural
    information
  • Understand details of binding mode
  • Identify potential interactions to improve
    potency
  • Structure(s) in homologues -gt selectivity
  • Identify regions where modifications can be made
  • e.g overcome physicochemical properties ADMET
    issues
  • Challenge of incorporating true drug-like
    properties

44
PDK1 hits from fragments
45
PDK1 hits from fragments
46
PDK1 hits from fragments
Side chain occupies solvent accessible pocket in
hinge cleft find compounds containing SeeD and
hydrophobic side chain
47
PDK1 hits from fragments
48
PDK1 hits from fragments
Chemistry around side chains to explore affinity
and solubility
49
PDK1 hits from fragments
Structures of 81903, 48319 and 49537 bound to PDK1
50
PDK1 hits from fragments
  • Synergy between high throughput crystallography,
    NMR, modelling, medicinal chemistry

51
Working with Proteins a personal per (and
retro) spective
  • The Past
  • What was a driver for MGMS?
  • Life before and after 1983
  • The Past and Present
  • Hardware developments, 1987 2007
  • Methods developments, 1987 2007
  • Determining and analysing structure
  • Predicting structure, conformation, mechanism and
    interactions
  • Structure-based drug discovery
  • The Future
  • Priorities for the next decade

52
Priorities for next 10 years
  • Graphics and computational hardware
  • Will continue to get faster, year on year
  • Will enable new science, but not the barrier

53
Priorities for next 10 years
  • Modelling protein conformation, mechanism and
    interactions
  • Experimental data will inform empirical methods
  • Computing power will allow increased use of more
    advanced models MM-PBSA, QM-based
  • Challenge remains entropy and its effects
    experiments report on ensembles

54
Priorities for next 10 years
  • Structure-based drug discovery
  • Interface between structure, modelling and
    chemistry in design of synthetically tractable
    compounds
  • Experimental data will improve empirical scoring
  • Models to predict / design drug-like properties

55
(No Transcript)
56
Acknowledgements
  • York
  • Leo Caves
  • Andy Raine
  • Tom Oldfield
  • Mike Hartshorn
  • Gaby Kuschert
  • Dave Edwards
  • Karen Hand
  • Richard Greaves
  • Chandra Verma
  • Pawel Herzyk
  • Steph Makins
  • Edward Croft
  • Sarah Done
  • Ollie Barker
  • Ana Rodrigues
  • Tom Davies
  • Derek Smith
  • Craig Elliott
  • Vernalis
  • Lisa Wright
  • Alan Surgenor
  • James Murray
  • Pawel Dokurno
  • Christine Richardson
  • Nicolas Foloppe
  • Ijen Chen
  • Xavier Barril
  • Martin Drysdale
  • Lee Walmsley
  • Ben Davis
  • Heather Simmonite
  • Christophe Fromont
  • Brian Dymock
  • Paul Brough
  • Harry Finch
  • David Knowles

57
1959
Write a Comment
User Comments (0)
About PowerShow.com